پیوندهای مفید
آمار
| تعداد نشریات | 20 |
| تعداد شماره‌ها | 1,149 |
| تعداد مقالات | 10,518 |
| تعداد مشاهده مقاله | 45,415,493 |
| تعداد دریافت فایل اصل مقاله | 11,291,284 |
Glypican-3 Expression in Patients with Oral Squamous Cell Carcinoma | ||
| Journal of Dentistry | ||
| مقاله 11، دوره 21، شماره 2 - شماره پیاپی 67، شهریور 2020، صفحه 141-146 اصل مقاله (466.73 K) | ||
| نوع مقاله: Original Article | ||
| شناسه دیجیتال (DOI): 10.30476/dentjods.2019.84541.1089 | ||
| نویسندگان | ||
| Azadeh Andisheh-Tadbir1؛ Amir Saeed Goharian2؛ Mohammad Ali Ranjbar* 3 | ||
| 1Oral and Dental Disease Research Center, Dept. of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran. | ||
| 2Undergraduate Student, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran. | ||
| 3Dept. of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran. | ||
| چکیده | ||
| Statement of the Problem: Oral squamous cell carcinoma (OSCC) is a malignant neoplasm that affect the structures or tissues of the mouth. Early diagnosis of these tumors is important to improve the outcome of treatment. Therefore, using pathological techniques based on molecular markers may be useful for optimal diagnosis and treatment. Glypican-3(GPC3) is involved in regulation of cell proliferation and morphogenesis and is abundant during embryogenesis and organogenesis but is limited in most of adult tissues. GPC3 overexpression has a role in carcinogenesis. Purpose: The aim of the present study was to investigate GPC3 expression in the non-neoplastic oral epithelium and oral squamous cell carcinoma. Materials and Method: In this cross-sectional study, 45 patients with OSCC (30 males and 15 females) with a mean age 52.3 of selected from Oral Pathology Department of Shiraz Dental School were enrolled. The control group was consisted of 15 cases of normal oral epithelium. Glypican-3 expression was assessed by using immunohistochemical methods. Results: Non neoplastic tissues were GPC3 negative. Frequency of GPC3 positivity in tumoral tissues was recorded as 73.3% (33 cases) which was significantly higher than non-neoplastic tissues (p < 0.001). The clinicopathologic features of GPC3 expression demonstrated no association with clinicopathologic parameters except tumor size. Conclusion: GPC3 was over expressed at protein level in oral squamous cell carcinoma, but its potential use for diagnostic and therapeutic purposes required further investigation. | ||
| کلیدواژه‌ها | ||
| Glypican-3؛ Immunohistochemistry؛ Squamous cell carcinoma | ||
|
سایر فایل های مرتبط با مقاله
|
||
| مراجع | ||
|
1. Monteiro LS, Diniz-Freitas M, Warnakulasuriya S, Garcia-Caballero T, Forteza J, Fraga M. An immunohistochemical score to predict the outcome for oral squamous cell carcinoma. J Oral Pathol Med. 2018; 47: 375–381. [PubMed] [Google Scholar]
2. Epstein JB, Wan LS, Gorsky M, Zhang L. Oral lichen planus: progress in understanding its malignant potential and the implications for clinical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003; 96: 32– 37. [PubMed] [Google Scholar]
3. Mithani SK, Mydlarz WK, Grumbine FL, Smith IM, Califano JA. Molecular genetics of premalignant oral lesions. Oral Dis. 2007; 13: 126–133. [PubMed] [Google Scholar]
4. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest. 2001; 108: 497–501. [PMC free article] [PubMed] [Google Scholar]
5. Wang F, Jing X, Wang T, Li G, Li T, Zhang Q, et al. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm. Am J Clin Pathol. 2012; 137: 937–945. [PubMed] [Google Scholar]
6. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res. 2004; 64: 2418–2423. [PubMed] [Google Scholar]
7. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer. 2002; 2: 521–528. [PubMed] [Google Scholar]
8. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005; 65: 6245–6254. [PubMed] [Google Scholar]
9. Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer. 2003; 103: 455–465. [PubMed] [Google Scholar]
10. Song HH, Shi W, Xiang YY, Filmus J. The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem. 2005; 280: 2116–2125. [PubMed] [Google Scholar]
11. Grozdanov PN, Yovchev MI, Dabeva MD. The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest. 2006; 86: 1272–1284. [PubMed] [Google Scholar]
12. Pellegrini M, Pilia G, Pantano S, Lucchini F, Uda M, Fumi M, et al. Gpc3 expression correlates with the phenotype of the Simpson-Golabi-Behmel syndrome. Dev Dyn. 1998; 213: 431–439. [PubMed] [Google Scholar]
13. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. 2008; 129: 899–906. [PubMed] [Google Scholar]
14. Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, et al. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol. 2009; 22: 824–832. [PubMed] [Google Scholar]
15. Man XB, Tang L, Zhang BH, Li SJ, Qiu XH, Wu MC, et al. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver Int. 2005; 25: 962–966. [PubMed] [Google Scholar]
16. Filmus J, Capurro M. The role of glypican-3 in the regulation of body size and cancer. Cell Cycle. 2008; 7: 2787–2790. [PubMed] [Google Scholar]
17. Kwack MH, Choi BY, Sung YK. Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells. Mol Cells. 2006; 21: 224–228. [PubMed] [Google Scholar]
18. Nakatsura T, Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs. 2005; 19: 71–77. [PubMed] [Google Scholar]
19. Lü ZL, Luo DZ, Wen JM. Expression and significance of tumor-related genes in HCC. World J Gastroenterol. 2005; 11: 3850–3854. [PMC free article] [PubMed] [Google Scholar]
20. Li BD, Zhao QC, Zhu YT, Zhang FQ, Dou KF. Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells. Zhonghua Wai Ke Za Zhi. 2006; 44: 458–462. [PubMed] [Google Scholar]
21. Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut. 2001; 48: 558–564. [PMC free article] [PubMed] [Google Scholar]
22. Akutsu N, Yamamoto H, Sasaki S, Taniguchi H, Arimura Y, Imai K, et al. Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma. World J Gastroenterol. 2010; 16: 3521–3528. [PMC free article] [PubMed] [Google Scholar]
23. Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res. 2004; 10: 6612–6621. [PubMed] [Google Scholar]
24. He H, Fang W, Liu X, Weiss LM, Chu PG. Frequent expression of glypican-3 in Merkel cell carcinoma: an immunohistochemical study of 55 cases. Appl Immunohistochem Mol Morphol. 2009; 17: 40–46. [PubMed] [Google Scholar]
25. Okoń K. Glypican-3 is expressed in chromophobe renal cell carcinoma . Pol J Pathol. 2008;59:15–20. [PubMed] [Google Scholar]
26. Mounajjed T, Zhang L, Wu TT. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms. Hum Pathol. 2013 Apr; 44: 542–550. [PubMed] [Google Scholar]
27. Umezu T, Shibata K, Shimaoka M, Kajiyama H, Yamamoto E, Ino K, et al. Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo. Cancer Sci. 2010; 101: 143–148. [PubMed] [Google Scholar]
28. Khan S, Blackburn M, Mao DL, Huber R, Schlessinger D, Fant M. Glypican-3 (GPC3) expression in human placenta: localization to the differentiated syncytiotrophoblast. Histol Histopathol. 2001; 16: 71–78. [PubMed] [Google Scholar]
29. Liu B, Paranjpe S, Bowen WC, Bell AW, Luo JH, Yu YP, et al. Investigation of the role of glypican 3 in liver regeneration and hepatocyte proliferation. Am J Pathol. 2009; 175: 717–724. [PMC free article] [PubMed] [Google Scholar]
30. Pantanowitz L, Otis CN. Glypican-3 immunohistochemistry in the ovary. Histopathology. 2008; 53: 115–117. [PubMed] [Google Scholar]
31. Ushiku T, Uozaki H, Shinozaki A, Ota S, Matsuzaka K, Nomura S, et al. Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and alpha-fetoprotein-producing gastric carcinomas. Cancer Sci. 2009; 100: 626–632. [PubMed] [Google Scholar]
32. Iglesias BV, Centeno G, Pascuccelli H, Ward F, Peters MG, Filmus J, et al. Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histol Histopathol. 2008; 23: 1333–1340. [PubMed] [Google Scholar]
33. Gonzalez AD, Kaya M, Shi W, Song H, Testa JR, Penn LZ, et al. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol. 1998; 141: 1407–1414. [PMC free article] [PubMed] [Google Scholar]
34. Kim H, Xu GL, Borczuk AC, Busch S, Filmus J, Capurro M, et al. The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol. 2003; 29: 694–701. [PubMed] [Google Scholar]
35. Valsechi MC, Oliveira AB, Conceição AL, Stuqui B, Candido NM, Provazzi PJ, et al. GPC3 reduces cell proliferation in renal carcinoma cell lines. BMC Cancer. 2014; 14: 631–642. [PMC free article] [PubMed] [Google Scholar]
36. Li YS, Milner PG, Chauhan AK, Watson MA, Hoffman RM, Kodner CM, et al. Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. Science. 1990; 250: 1690–1694. [PubMed] [Google Scholar]
37. Stadlmann S, Gueth U, Baumhoer D, Moch H, Terracciano L, Singer G. Glypican-3 expression in primary and recurrent ovarian carcinomas. Int J Gynecol Pathol. 2007; 26: 341–344. [PubMed] [Google Scholar]
38. Aviel-Ronen S, Lau SK, Pintilie M, Lau D, Liu N, Tsao MS, Jothy S. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol. 2008; 21: 817–825. [PubMed] [Google Scholar]
39. Nemolato S, Fanni D, Naccarato AG, Ravarino A, Bevilacqua G, Faa G. Lymphoepithelioma-like hepatocellular carcinoma: A case report and a review of the literature. World J Gastroenterol. 2008; 14: 4694–4696. [PMC free article] [PubMed] [Google Scholar]
40. Zou S, Cao N, Cheng D, Zheng R, Wang J, Zhu K, et al. Enhanced apoptosis of ovarian cancer cells via nanocarrier- mediated codelivery of siRNA and doxorubicin. Int J Nanomedicine. 2012; 7: 3823–3835. [PMC free article] [PubMed] [Google Scholar]
41. Ho M, Kim H. Glypican-3: a new target for cancer immunotherapy. Eur J Cancer. 2011; 47: 333–338. [PMC free article] [PubMed] [Google Scholar]
42. Capurro MI, Xu P, Shi W, Li F, Jia A, Filmus J. zlypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell. 2008; 14: 700–711. [PubMed] [Google Scholar]
43. Srivastava K, Srivastava A, Mittal B. Potential biomarkers in gallbladder cancer: present status and future directions. Biomarkers. 2013; 18: 1–9. [PubMed] [Google Scholar]
44. Qi XH, Wu D, Cui HX, Ma N, Su J, Wang YT, et al. Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells. Mol Med Rep. 2014; 10: 3177–3184. [PubMed] [Google Scholar]
45. Tanaka SS, Kojima Y, Yamaguchi YL, Nishinakamura R, Tam PP. Impact of WNT signaling on tissue lineage differentiation in the early mouse embryo. Dev Growth Differ. 2011; 53: 843–856. [PubMed] [Google Scholar]
46. Gao W, Ho M. The role of glypican-3 in regulating Wnt in hepatocellular carcinomas. Cancer Rep. 2011; 1: 14–19. [PMC free article] [PubMed] [Google Scholar]
47. Andisheh-Tadbir A, Ashraf MJ, Gudarzi A, Zare R. Evaluation of Glypican-3 expression in benign and malignant salivary gland tumors. Oral Biol Craniofac Res. 2019; 9: 63–66. [PMC free article] [PubMed] [Google Scholar]
48. De Cat B, Muyldermans SY, Coomans C, Degeest G, Vanderschueren B, Creemers J, et al. Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J Cell Biol. 2003; 163: 625–635. [PMC free article] [PubMed] [Google Scholar]
49. Filmus J, Capurro M. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J. 2013; 280: 2471–2476. [PubMed] [Google Scholar]
50. Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006; 12: 2689–2697. [PubMed] [Google Scholar]
51. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, et al. Phase I trial of a glypican- 3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res. 2012; 18: 3686–3696. [PubMed] [Google Scholar]
52. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastro enterology. 2003; 125: 89–97. [PubMed] [Google Scholar]
53. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003; 306: 16–25. [PubMed] [Google Scholar] | ||
|
آمار تعداد مشاهده مقاله: 2,512 تعداد دریافت فایل اصل مقاله: 1,776 |
||
